Acta Pharmaceutica

Acta Pharmaceutica is published by Sciendo, a De Gruyter company and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Solubulity and Delivery Systems, Advanced Drug Delivery Systems and Analytical Methods in Pharmaceuticals, together about 34% of its articles. Its main subfields are Pharmaceutical Science and Organic Chemistry. (generated from OpenAlex topic counts and CAS ranking data)

Acta Pharmaceutica (AP) is a quarterly journal dealing with all branches of pharmaceutical and related sciences, respecting openness, authenticity, ethics and transparency. It is an international, scientific, multidisciplinary journal, which brings articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With a strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice, in the form of original research papers (articles), preliminary and short communications, and reviews (systematic/critical, mini reviews, meta-analysis and bibliometric-analysis reviews). Book reviews are published also.Acta Pharmaceutica is a single-blind, peer-reviewed journal (at least two independent referees after the desk pre-review). It is also an open access journal (“gold” OA) with “early bird” sections on editorial manager platform. To reach the highest standards in publication ethics all the parties (authors, editors, reviewers) are required to behave responsibly and ethically. This implies submittance by authors on an exclusive basis, of only their own and new data; novelty and originality are prioritized. Also, secure handling of confidential data by reviewers and editors is a must.All submitted manuscripts should conform to generally accepted usage in composition of research papers. For technical requirements author should consult Information for authors and the recent issues.Submission of materials generated by AI is discouraged. Neither is allowed to submit paper-mills-produced materials. Otherwise retraction policy might be activated. AI must not be used during reviewing process either.The use of official institutional e-mail address during paper submittance and afterwards is strongly recommended. Otherwise, Authentication letter issued and signed by the affiliating institution, during submission process (template provided at the end of Instructions for Authors) is expected.Numerous topics are covered by Acta Pharmaceutica from analytics of drugs, biochemistry (pharmaceutical/clinical), biophysics, bioinformatics, cell biology, clinical pharmacy, cosmetology, drug design/delivery/disposition and stability, drug metabolism, genetics, medicine (including diagnostics and therapy), molecular modelling/docking studies, nanomedicine, networking and computational drug designing, network pharmacology, peptide and

From the journal's Aims & Scope

Research area (LetPub): PHARMACOLOGY & PHARMACY

Editorial board by country: none in mainland China; most named Croatia 13, Slovenia 5 (18 members with a country) Editorial board ↗Publisher website · 2026-09-29

CAS Journal Ranking

Database indexing

SCIEScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

1.77LetPub · 2026-09-13

Impact factor (publisher)

18Publisher website · 2026-09-29

CiteScore 2026-06

3.2LetPub · 2026-09-13

CiteScore (publisher)

32Publisher website · 2026-09-29

SJR 2026-06

0.46LetPub · 2026-09-13

SNIP 2026-06

0.53LetPub · 2026-09-13

h-index

49LetPub · 2026-09-13

h-index

63OpenAlex · 2026-10-01

i10-index

479OpenAlex · 2026-10-01

2-year mean citedness

2.5OpenAlex · 2026-10-01

Self-citation rate

0%LetPub · 2026-09-13

Share of gold OA articles

100%LetPub · 2026-09-13

Volume

Articles per year

41LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Average review time (community reports)

over 12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

EasyLetPub · 2026-09-13

Submission to publication (journal-reported)

about 20 weeksDOAJ · 2026-10-25

Peer review

Single anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

• APC information ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Sciendo, a De Gruyter company

Country or region

CROATIA

Language

English

Frequency

Quarterly

Founded

1951

ISSN

1330-0075

Electronic ISSN

1846-9558

Official links

• Journal homepage ↗DOAJ
• Author guidelines ↗DOAJ
• Aims & Scope ↗DOAJ
• APC information ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ
• Peer review process ↗DOAJ
• Editorial board ↗DOAJ
• Plagiarism policy ↗DOAJ